Flurbiprofen
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Flurbiprofen: Acromesomelic dysplasia, Hunter-Thompson type
One-Sentence Summary
Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) that blocks cyclooxygenase (COX) enzymes. The TxGNN model predicts it for acromesomelic dysplasia, Hunter-Thompson type (score 0.9999), but no clinical trials and no publications currently support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Flurbiprofen is known as a non-selective COX inhibitor, which reduces inflammation and pain.
Acromesomelic dysplasia, Hunter-Thompson type is a rare skeletal dysplasia caused by loss-of-function mutations in the CDMP1/GDF5 gene, which disrupts GDF5/BMP signalling during bone development. COX inhibition has no known effect on this signalling defect, so no mechanistic link can be established.
The very high score most likely reflects the model’s association of the drug with musculoskeletal conditions in general, not a pharmacological rationale. This prediction should be regarded as a computational hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name |
|---|---|
| 01912038 | FLURBIPROFEN |
| 01912046 | FLURBIPROFEN |
Both authorizations are currently valid single-ingredient products.
Safety Considerations
- Contraindication-related conditions (from the data compiled for this report, not label text): hypertension, kidney disease, liver disease, gallbladder disease, peptic ulcer disease (including active ulcer), blood coagulation disease, myocardial infarction and other cardiovascular or heart disease, hemoglobinopathy, and substance abuse/dependence. These should be confirmed against the official product monograph.
- Drug Interactions: 100 interactions were identified. Examples at moderate level include acetylsalicylic acid, corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide), metformin, glimepiride, chlorpropamide, aprepitant, mesalazine and balsalazide. Minor-level examples include famotidine, cimetidine and linaclotide.
Please refer to the package insert for complete safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or publications, and no plausible mechanism links COX inhibition to the GDF5/BMP defect underlying this disease. The evidence level is L5 (model prediction only).
To proceed, the following is needed:
- Any preclinical or mechanistic evidence linking flurbiprofen to GDF5/BMP signalling or to this disease
- Detailed mechanism of action data
- Health Canada product monograph warnings and contraindications
- A safety review for use in the affected (largely paediatric) population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.